The Acute Kidney Outreach to Prevent Deterioration and Death trial: a large pilot study for a cluster-randomized trial

被引:4
|
作者
Thomas, Mark E. [1 ]
Abdelaziz, Tarek S. [2 ]
Perkins, Gavin D. [3 ]
Sitch, Alice J. [4 ,5 ,6 ]
Baharani, Jyoti [1 ]
Temple, R. Mark [1 ]
机构
[1] Univ Hosp Birmingham NHS Fdn Trust, Birmingham Heartlands Hosp, Dept Renal Med, Birmingham, W Midlands, England
[2] Cairo Univ, Sch Med, Dept Internal Med, Nephrol Unit, Cairo, Egypt
[3] Univ Warwick, Warwick Med Sch, Warwick Clin Trials Unit, Coventry, W Midlands, England
[4] Univ Birmingham, Inst Appl Hlth Res, Birmingham, W Midlands, England
[5] Univ Hosp Birmingham NHS Fdn Trust, NIHR Birmingham Biomed Res Ctr, Birmingham, W Midlands, England
[6] Univ Birmingham, Birmingham, W Midlands, England
基金
美国国家卫生研究院;
关键词
acute kidney injury; complex multifactorial intervention; controlled clinical trial; outreach; rapid response systems; TIME ELECTRONIC ALERT; NEPHROLOGY CONSULTATION; INJURY; MORTALITY; IMPACT; OUTCOMES; COSTS; AKI;
D O I
10.1093/ndt/gfz246
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background and Objectives. The Acute Kidney Outreach to Reduce Deterioration and Death trial was a large pilot study for a cluster-randomized trial of acute kidney injury (AKI) outreach. Methods. An observational control (before) phase was conducted in two teaching hospitals (9miles apart) and their respective catchment areas. In the intervention (after) phase, a working-hours AKI outreach service operated for the intervention hospital/area for 20weeks, with the other site acting as a control. All AKI alerts in both hospital and community patients were screened for inclusion. Major exclusion criteria were patients who were at the end of life, unlikely to benefit from outreach, lacking mental capacity or already referred to the renal team. The intervention arm included a model of escalation of renal care to AKI patients, depending on AKI stage. The 30-day primary outcome was a combination of death, or deterioration, as shown by any need for dialysis or progression in AKI stage. A total of 1762 adult patients were recruited; 744 at the intervention site during the after phase. Results. A median of 3.0 non-medication recommendations and 0.5 medication-related recommendations per patient were made by the outreach team a median of 15.7h after the AKI alert. Relatively low rates of the primary outcomes of death within 30days (11-15%) or requirement for dialysis (0.4-3.7%) were seen across all four groups. In an exploratory analysis, at the intervention hospital during the after phase, there was an odds ratio for the combined primary outcome of 0.73 (95% confidence interval 0.42-1.26; P=0.26). Conclusions. An AKI outreach service can provide standardized specialist care to those with AKI across a healthcare economy. Trials assessing AKI outreach may benefit from focusing on those patients with 'mid-range' prognosis, where nephrological intervention could have the most impact.
引用
收藏
页码:657 / 665
页数:9
相关论文
共 50 条
  • [21] Decreasing polypharmacy in older adults with cancer: A pilot cluster-randomized trial protocol
    Ramsdale, Erika
    Mohamed, Mostafa
    Holmes, Holly M.
    Zubkoff, Lisa
    Bauer, Jessica
    Norton, Sally A.
    Mohile, Supriya
    JOURNAL OF GERIATRIC ONCOLOGY, 2024, 15 (02)
  • [22] Multifaceted Intervention to Prevent Venous Thromboembolism in Patients Hospitalized for Acute Medical Illness: A Multicenter Cluster-Randomized Trial
    Roy, Pierre-Marie
    Rachas, Antoine
    Meyer, Guy
    Le Gal, Gregoire
    Durieux, Pierre
    El Kouri, Dominique
    Honnart, Didier
    Schmidt, Jeannot
    Legall, Catherine
    Hausfater, Pierre
    Chretien, Jean-Marie
    Mottier, Dominique
    PLOS ONE, 2016, 11 (05):
  • [23] Introduction of a Management Toolkit for Lewy Body Dementia: A Pilot Cluster-Randomized Trial
    O'Brien, John T.
    McKeith, Ian G.
    Thomas, Alan J.
    Bamford, Claire
    Vale, Luke
    Hill, Sarah
    Allan, Louise
    Finch, Tracy
    McNally, Richard
    Hayes, Louise
    Surendranathan, Ajenthan
    Kane, Joseph P. M.
    Dunn, Sarah
    Bentley, Allison
    Barker, Sally
    Mason, James
    Burn, David
    Taylor, John-Paul
    MOVEMENT DISORDERS, 2021, 36 (01) : 143 - 151
  • [24] The Acute Aphasia IMplementation Study (AAIMS): a pilot cluster randomized controlled trial
    Shrubsole, Kirstine
    Worrall, Linda
    Power, Emma
    O'Connor, Denise A.
    INTERNATIONAL JOURNAL OF LANGUAGE & COMMUNICATION DISORDERS, 2018, 53 (05) : 1021 - 1056
  • [25] Effectiveness of a gamification strategy to prevent childhood obesity in schools: a cluster-randomized controlled trial
    Pena, Sebastian
    Carranza, Macarena
    Cuadrado, Cristobal
    Espinoza, Paula
    Muller, Valeska
    Cerda, Ricardo
    PROCEEDINGS OF THE NUTRITION SOCIETY, 2020, 79 (OCE2) : E145 - E145
  • [26] Targeted Antibiotics for Trachoma: A Cluster-Randomized Trial
    Melo, Jason S.
    Aragie, Solomon
    Chernet, Ambahun
    Tadesse, Zerihun
    Dagnew, Adane
    Hailu, Dagnachew
    Haile, Mahteme
    Zeru, Taye
    Wittberg, Dionna M.
    Nash, Scott D.
    Callahan, E. Kelly
    Arnold, Benjamin F.
    Porco, Travis C.
    Lietman, Thomas M.
    Keenan, Jeremy D.
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (06) : 979 - 986
  • [27] Comparison of Media Literacy and Usual Education to Prevent Tobacco Use: A Cluster-Randomized Trial
    Primack, Brian A.
    Douglas, Erika L.
    Land, Stephanie R.
    Miller, Elizabeth
    Fine, Michael J.
    JOURNAL OF SCHOOL HEALTH, 2014, 84 (02) : 106 - 115
  • [28] Real-time surveillance system for patient deterioration: a pragmatic cluster-randomized controlled trial
    Rossetti, Sarah C.
    Dykes, Patricia C.
    Knaplund, Chris
    Cho, Sandy
    Withall, Jennifer
    Lowenthal, Graham
    Albers, David
    Lee, Rachel Y.
    Jia, Haomiao
    Bakken, Suzanne
    Kang, Min-Jeoung
    Chang, Frank Y.
    Zhou, Li
    Bates, David W.
    Daramola, Temiloluwa
    Liu, Fang
    Schwartz-Dillard, Jessica
    Tran, Mai
    Bokhari, Syed Mohtashim Abbas
    Thate, Jennifer
    Cato, Kenrick D.
    NATURE MEDICINE, 2025,
  • [29] Dexamethasone to prevent kidney scarring in acute pyelonephritis: a randomized clinical trial
    Neus Rius-Gordillo
    Natàlia Ferré
    Juan David González
    Zaira Ibars
    Ester Parada-Ricart
    Maria Gloria Fraga
    Sara Chocron
    Manuel Samper
    Carmen Vicente
    Jordi Fuertes
    Joaquín Escribano
    Pediatric Nephrology, 2022, 37 : 2109 - 2118
  • [30] Dexamethasone to prevent kidney scarring in acute pyelonephritis: a randomized clinical trial
    Rius-Gordillo, Neus
    Ferre, Natalia
    Gonzalez, Juan David
    Ibars, Zaira
    Parada-Ricart, Ester
    Fraga, Maria Gloria
    Chocron, Sara
    Samper, Manuel
    Vicente, Carmen
    Fuertes, Jordi
    Escribano, Joaquin
    PEDIATRIC NEPHROLOGY, 2022, 37 (09) : 2109 - 2118